Loading...
XSTO
CLBIO
Market cap35mUSD
Jul 11, Last price  
13.70SEK
1D
-0.36%
1Q
58.56%
Jan 2017
35.64%
IPO
41.28%
Name

Corline Biomedical AB

Chart & Performance

D1W1MN
P/E
P/S
34.32
EPS
Div Yield, %
Shrs. gr., 5y
5.44%
Rev. gr., 5y
55.82%
Revenues
10m
-60.95%
5,999,3831,787,6271,683,2561,037,089947,000638,0001,563,0001,064,0003,696,0007,062,00023,550,00025,030,0009,775,000
Net income
-23m
L+1,182.14%
-911,471-2,487,798-2,512,187-5,845,275-5,248,000-7,810,000-6,793,000-9,540,000-7,287,000-6,916,0002,329,000-1,809,000-23,194,000
CFO
-9m
L
0-2,759,348-2,318,929-4,231,183-7,211,000-4,978,000-4,104,000-13,839,000-5,066,000-4,835,000-6,452,000886,000-8,639,000
Earnings
Aug 21, 2025

Profile

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.
IPO date
Jun 03, 2015
Employees
14
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,775
-60.95%
25,030
6.28%
23,550
233.47%
Cost of revenue
(3,666)
(3,350)
824
Unusual Expense (Income)
NOPBT
13,441
28,380
22,726
NOPBT Margin
137.50%
113.38%
96.50%
Operating Taxes
549
Tax Rate
2.42%
NOPAT
13,441
28,380
22,177
Net income
(23,194)
1,182.14%
(1,809)
-177.67%
2,329
-133.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
16,792
537
26
BB yield
-8.77%
-0.17%
-0.01%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
4,341
Net debt
(17,668)
(17,013)
(26,211)
Cash flow
Cash from operating activities
(8,639)
886
(6,452)
CAPEX
(7,497)
(132)
(8,999)
Cash from investing activities
(7,497)
(10,621)
(8,999)
Cash from financing activities
16,792
537
26
FCF
13,536
39,070
11,355
Balance
Cash
17,668
17,012
26,210
Long term investments
1,000
1,000
Excess cash
17,179
15,762
25,034
Stockholders' equity
(145,056)
(61,877)
5,015
Invested Capital
231,970
155,193
89,574
ROIC
6.94%
23.19%
31.17%
ROCE
15.46%
30.41%
24.03%
EV
Common stock shares outstanding
21,811
21,677
21,491
Price
8.78
-41.07%
14.90
61.61%
9.22
-36.85%
Market cap
191,504
-40.71%
322,992
63.01%
198,145
-33.60%
EV
173,836
305,979
235,224
EBITDA
13,536
28,477
22,782
EV/EBITDA
12.84
10.74
10.33
Interest
32
26
Interest/NOPBT
0.24%
0.09%